As it presented final-stage trial results, Novartis said the new antimalarial drug it is developing is as effective as existing treatments and could help tackle rising drug resistance. The drug, ganaplacide/lumefantrine or GanLum, was created by the company and the Medicines for Malaria Venture, a non-profit.
Novartis' new malaria medicine GanLum sachets at the company's manufacturing site in Slovenia, October 30, 2024. Image credit: Novartis/Handout via Reuters
It was more than 97% effective at treating malaria in a phase III trial among 1,688 adults and children across 34 sites in 12 African countries, Novartis said.
Malaria still kills more than 600,000 people annually, most of them children under five in sub-Saharan Africa.
Fighting resistance
Existing treatments still work against the mosquito-borne disease – with an effectiveness of around 94% — but there is increasing concern about rising resistance to one of the key drugs used, artemisinin.
Artemisinin resistance was first observed in Cambodia around 20 years ago, before spreading around the Mekong region.
It is now increasingly a problem in African countries, with confirmed partial resistance in Eritrea, Rwanda, Uganda and Tanzania.
“Drug resistance is a growing threat to Africa, so new treatment options can’t come a moment too soon,” said Abdoulaye Djimdé, the trial lead and professor of parasitology and mycology at the University of Science, Techniques and Technologies of Bamako, Mali.
Jonathan E. Cohen 8 Aug 2025 If resistance becomes more widespread, the fear is that the existing therapies – known as artemisinin combination therapies – will stop working.
George Jagoe, head of access at MMV, likened the new drug to having a fire extinguisher ready for an approaching blaze, rather than being as unprepared as the world was when previous malaria drugs started to fail.
Ganaplacide is a new type of drug and represents the first major advance in decades, Novartis and an external scientist said.
“Finally, new compounds are being proven effective for the treatment of malaria,” Dr Alena Pance, senior genetics lecturer at the University of Hertfordshire, said.
GanLum works differently from previous antimalarials and, unlike many of those treatments, also blocks transmission by acting on the malaria parasite at the point where it can spread back from an infected human to the mosquito that bites them.
Novartis will now apply for regulatory approval, the company said, and expects GanLum to be available in countries within the next year to 18 months, on a non-profit basis.
